Leerink Partnrs lowered their FY2028 earnings per share estimates for Axsome Therapeutics in a research note issued on ...
H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares following ...
Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...
Shares of Axsome Therapeutics (NASDAQ: AXSM) are up on Tuesday. The jump comes as the S&P 500 (SNPINDEX: ^GSPC) lost 0.3% and ...
Truist raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares. The company’s Q4 ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Axsome Therapeutics (AXSM) is climbing nearly 4% after Swiss bank UBS increased its price target on the shares to $133 from $105. The bank is confident that the company's potential treatment for ...
Below is Validea's guru fundamental report for AXSOME THERAPEUTICS INC (AXSM). Of the 22 guru strategies we follow, AXSM rates highest using our Value Investor model based on the published ...
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback